Supplements

Best Practices: Practical Guidance in Treating Advanced NSCLC with Immunotherapy

Lung cancer is the second-most common type of cancer in the United States, including approximately 235,000 new cases each year, 84% of which are non–small-cell lung cancer (NSCLC). Although lung cancer remains the leading cause of cancer mortality—outweighing prostate, breast, and colon cancer combined—advances in treatment are improving patient outcomes and decreasing mortality.

View Supplement

TLG2289-4-cover
Best Practices: Education for Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

For many patients with non–small-cell lung cancer (NSCLC), immunotherapy is now becoming the standard of care. Immunotherapy given as monotherapy or in combination with other agents has contributed to promising results in NSCLC, with the earliest results observed in 2015 with nivolumab, and subsequently leading to FDA approval of 6 agents.

View Supplement

Best Practices: Immune-Related Adverse Event Management in Patients with Advanced NSCLC Treated with Immune Checkpoint Inhibitors

The American Cancer Society estimates 236,740 new cases of lung cancer and 130,180 deaths from lung cancer in 2022, second only to prostate cancer in men and breast cancer in women.1

View Supplement

Novel BCMA-Targeting Bispecific T-cell Engagers: Emerging Role in Advanced MM

Multiple myeloma (MM) is a malignancy of plasma cells that accumulate in the bone marrow and/or extramedullary sites, leading to complications such as renal failure, bone destruction, and hypercalcemia.

View Supplement

Best Practices: Biomarkers and Treatment Selection in the Management of Advanced NSCLC

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of patients with advanced non–small-cell lung cancer (NSCLC) by demonstrating significantly better outcomes and tolerability than conventional chemotherapy.

View Supplement

2022 Midyear Review: Non–Small-Cell Lung Cancer

We are pleased to provide highlights of important and potentially practice-changing developments in immunotherapy of non–small-cell lung cancer (NSCLC) presented at the 2022 annual meetings of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). In this print supplement, we will summarize pivotal clinical data that were presented on immune checkpoint inhibitor therapy of NSCLC at both of these key meetings.

A total of 25 data presentations from AACR 2022 and ASCO 2022 are summarized in this resource. We hope that the information reviewed here can be applied to clinical practice and offers valuable insights into the important progress that is being made in the care of patients with NSCLC.

View Supplement

2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments

Supported through funding from

Bristol Myers Squibb

Dual immunotherapy for cancer has been one of the most successful modes of treatment researched and developed in recent years, with many new studies having been completed this past year. Immunotherapy has been used in the past for oncological treatments with monotherapy and in combination with chemotherapy; these new studies provide data on the success of combinations of various monoclonal antibodies for treatment of solid tumors.

These major research advances have been compiled from presentations at the 2021 American Society of Clinical Oncology and 2021 European Society for Medical Oncology annual meetings, in addition to manuscripts published in key journals. This year in review summarizes data on these important and innovative therapies.

View Supplement

Mechanism of Pathway: Considerations of Cytogenetic and Molecular Mutation Status for Patients with Acute Myeloid Leukemia: A Deeper Look at the Role of Diagnostic and Ongoing Testing Across the Care Continuum

Highlights

  • The combination of cytogenetic information provided by karyotype analysis and the identification of molecular abnormalities is crucial to the management of acute myeloid leukemia (AML), as it may inform treatment strategies and it provides invaluable prognostic information regarding remission rates, relapse risk, and overall survival outcomes
  • FLT3-ITD, ASXL1, RUNX1, TP53, and KIT mutations have been linked to poor prognosis
  • While the evidence is mixed for the prognostic value of FLT3-TKD (~7% of patients), numerous studies have demonstrated the negative prognostic influence of FLT3-ITD (~25% of patients)
  • AML is characterized by clonal evolution, and FLT3 mutation status may change between initial treatment and relapse. It may be important to perform genetic testing multiple times over the care continuum

View Supplement

Mechanism of Action Magnifier – 2016 Desk Reference

Welcome to the inaugural edition of our annual Mechanism of Action Magnifier™! The Magnifier series is an exclusive supplement brought to you by the publishers of Personalized Medicine in Oncology (PMO) to delve into the biochemical interaction through which an oncology drug produces its pharmacological effect.

View Supplement

Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?
  • Review of the Initial Results from Basket Trials
  • Implications of Initial Results in Patients with Metastatic Cancer and Diagnostic Ambiguity
  • Improving Diagnostic Certainty: The Role of Molecular Assays in Challenging Cases
  • Performance of the CancerTYPE ID Molecular Classifier

View Supplement

Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets
  • Phosphatidylserine (PS) is an immune checkpoint distinct from PD-1/PD-L1, CTLA-4, and other antagonists or agonists of T-cell activation
  • Tumors compromise the body’s normal immunosuppressive process of clearance/disposal of dying cells through PS-signaling mechanisms to evade immune detection
  • PS exposure in the tumor microenvironment is immunosuppressive and increases in response to chemotherapy and radiation therapy
  • Bavituximab is an investigational monoclonal antibody that targets PS and is believed to override PS-mediated immunosuppressive signaling in tumors prevalent in the tumor microenvironment, as well as to provide an immune-activating signal through Fc-Îł receptor signaling

View Supplement

Lowering Costs Through Effective Hematologic Malignancy Diagnosis
Optimal management of hematologic malignancies requires an early, accurate, complete, and clear diagnosis. Hematologic malignancies, however, are frequently misdiagnosed. Studies have demonstrated misdiagnosis in up to 27% of leukemia, 18% of lymphoma, and 75% of Burkitt lymphoma cases.

View Supplement

Diagnosis and Management of Polycythemia Vera
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm (MPN) that has undergone a major evolution over the past decade.

View Supplement

Mechanism of Action: Key Advances in Hematology Oncology
As evidenced by the 2013 annual meetings of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA), the pace at which scientific knowledge is influencing cancer drug development is astounding. Breakthroughs in our collective understanding of the underlying biology of solid and liquid tumors have revolutionized cancer treatment compared with as few as 5 years ago.

View Supplement